Proprietary Remedies IV

download Proprietary Remedies IV

of 44

Transcript of Proprietary Remedies IV

  • 8/18/2019 Proprietary Remedies IV

    1/44

    REMEDIES FOR BREACH

    OF TRUST

    04/01/16EQUITY & TRUST II

    (DR. ZURAIDAH)1

  • 8/18/2019 Proprietary Remedies IV

    2/44

    Learning Objectives

    • Students wi be abe !

    i"  T# $n#w t%e re&edies '#r breac% #'trust

    ii"  T# understand t%e c#nce(t #' (ers#nare&edies against t%e trustee

    iii" T# earn ab#ut (r#(rietar) re&edies

    and its advantagesiv" T# understand t%e c#nce(t #' tracingand its i&(e&entati#n

    04/01/16EQUITY & TRUST II

    (DR. ZURAIDAH)2

  • 8/18/2019 Proprietary Remedies IV

    3/44

    Intr#ducti#n

    • Re&edies are avaiabe t# guardagainst breac% #' trust*

     T%ese can be divided t# tw#+i" ,ers#na re&edies against trustee

    ii" ,r#(rietar) re&edies avaiabe t#

    t%e bene-ciaries*

    04/01/16EQUITY & TRUST II

    (DR. ZURAIDAH)3

  • 8/18/2019 Proprietary Remedies IV

    4/44

    ,ers#na Re&edies againsttrustee

    • It can be divided t# t%ree!

    i" Measure #' iabiit)

    ii" Invest&entsiii" Interest

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    4

  • 8/18/2019 Proprietary Remedies IV

    5/44

    Measure #' iabiit)

    • .%en t%ere is a breac% #' trust/ direct)#r indirect)/ t%ere wi be interest*

    • I' t%ere is unaut%#rised (r#-t+ trusteewi %ave t# acc#unt '#r (r#-t*

    •  Trustee wi be iabe #n) '#r #sesarising '#r& t%e breac% #' trust

    •  T%e) are n#t insurer t# t%e trust(r#(ert)

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    5

  • 8/18/2019 Proprietary Remedies IV

    6/44

    Di&es v Sc#tt 01234" 5 Russ126

    •  T%e) are n#t a#wed t# set #7 (r#-t &adein #ne transacti#n against #ss in an#t%er*

    • Suc% (r#-ts be#nged t# bene-ciaries

    •  Trustee cann#t cai& t%e (r#-t just t#essen t%eir #wn iabiit) '#r #ss causedb) a breac%*

     T%ese wi n#t a(() i' (r#-t and #ss canbe seen t# be (art #' t%e sa&e transacti#n

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    6

  • 8/18/2019 Proprietary Remedies IV

    7/44

    Invest&ent

    1" I' trustee &a$e unaut%#risedinvest&ent/ t%e) wi be iabe '#ran) #ss w%ic% is incurred w%en t%e

    invest&ent is reaised

    3" .%ere unaut%#rised invest&ent arei&(r#(er) retained/ t%e &easure #'

    iabiit) is t%e di7erence betweent%e (resent vaue #' invest&ent andt%e (rice

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    7

  • 8/18/2019 Proprietary Remedies IV

    8/44

    8" I' trustee are directed b) trust instru&entt# &a$e a s(eci-c invest&ent but t%e)eit%er+

    i" Ma$e n# invest&ent #r

    ii" invest s#&ew%ere*

     T%e) wi be iabe t# su(() t%e aunt #'t%e s(eci-c invest&ent 9 %ad t%e) investedat (r#(er ti&e*

    5" A trustee used trust ne) '#r %is #wnbusiness 9 iabe t# %#d '#r (r#-t

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    8

  • 8/18/2019 Proprietary Remedies IV

    9/44

    Interest

    • Re(ace a #ss wit% an interest

     Traditi#na rate 5 :• Ma) be iabe '#r %ig%er rate at t%e

    discreti#n #' t%e c#urt

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    9

  • 8/18/2019 Proprietary Remedies IV

    10/44

    ,RO,RIETAR; REMEDIES

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    10

  • 8/18/2019 Proprietary Remedies IV

    11/44

    Meaning ,R

    • A $ind #' re&ed) w%ere t%e (ainti7can cai& t%at (r#(ert) in t%e %ands#' t%e de'endant is t# be treated ast%at #' (ainti7*

    • It is n#t t%e sa&e as

  • 8/18/2019 Proprietary Remedies IV

    12/44

    • It entites t%e (ainti7 t# treat an)(r#(ert)/ usua) ne)/ in t%e%ands #' t%e de'endant as being t%e

    (ainti7 t# t%e e>tent t%at %e cancai& re(a)&ent in 'u regardess #'t%e de'endant=s ins#venc)*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    12

    t t

  • 8/18/2019 Proprietary Remedies IV

    13/44

    vantages r#(r etar)Re&ed) c#&(ared t#

    ,ers#na Re&ed)• 1" Satis'acti#n #' t%e (ainti7=sde&and d#es n#t de(ends #n t%es#venc) #' t%e de'endant

    • 3"T%e (ainti7 wi be abe t# ta$eadvantages #' t%e increase in vaue#' t%e said (r#(ert)

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    13

  • 8/18/2019 Proprietary Remedies IV

    14/44

    • It c#ncerns an inc#&e (r#ducingassets w%ereb) interest wi becacuated 'r#& t%e date #n w%ic%

    t%e (r#(ert) ca&e t# t%e de'endant=s%and*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    14

  • 8/18/2019 Proprietary Remedies IV

    15/44

    • E?uitabe ,r#(rietar) Re&ed) is$n#wn as trustee

    •  T%is is a $ind #' re&ed) w%ic%entites a cai&ant t# treat s(eci-c(r#(ert) as %is #wn

    •  Tw# t)(es+

    • A" Tracing at C#&n Law

    • B" Tracing at E?uit)

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    15

  • 8/18/2019 Proprietary Remedies IV

    16/44

    0i" Tracing at C#&n Law

    •  T%e #wner #' (r#(ert) can cai& '#rt%e return #' suc% (r#(ert) #r its vaue

    • I' t%e (r#(ert) %ad been c#nverted t##t%er (r#(ert) and can be identi-abe#n its (%)sica sense/ t%e bene-ciar)

    sti can cai& against t%e trust(r#(ert)

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    16

  • 8/18/2019 Proprietary Remedies IV

    17/44

    • H#wever/ i' t%e (r#(ert) %asc%anged eit%er in cas%@#t%er'#r&@&i>ed wit% #t%er ne)/ t%e

    tracing under c#&n aw is n##nger (#ssibe*

    • S# #ng as t%e (r#(ert) is

    identi-abe/ it can be rec#vered*

    • Once &i>ed/ it is n#t traceabe

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    17

  • 8/18/2019 Proprietary Remedies IV

    18/44

    • Taylor v Plumer (1815) 3 M & S

    562. L#rd Eenb#r#ug%+• It &a$es n# di7erence in reas#n #r

    aw int# w%at #t%er '#r&/ di7erent'r#& t%e #rigina/ t%e c%ange &a)

    %ave been &ade/ w%et%er int# t%at#' (r#&iss#r) n#tes '#r t%e securit)#' t%e ne) w%ic% was (r#ducedb) t%e sae #' g##ds i' t%e(rinci(a * * * '#r t%e (r#duct #' #rsubstitute '#r t%e #rigina t%ing sti-s t%e &ature #' t%e ting it se'/

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    18

  • 8/18/2019 Proprietary Remedies IV

    19/44

    • as #ng as it can be ascertainabe t#be suc% and t%e rig%t #n) ceasesw%en t%e &eans #' ascertain&ent

    'ai/ w%ic% is t%e case w%en t%esubject is turned int# ne) and&i>ed and c#'#unded in a genera

    &ass #' t%e sa&e directi#n*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    19

  • 8/18/2019 Proprietary Remedies IV

    20/44

    ii" Tracing Under E?uit)

    •  T%e c#nce(t is re wider ande>ibe

    • It a((ies n#t #n) w%en t%e (r#(ert)is in t%e %ands #' trustees #r #t%er-duciaries/ but as# in a c#&&erciac#nte>t*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    20

  • 8/18/2019 Proprietary Remedies IV

    21/44

    c".%# can trace

    • It is n#t c#n-ned t# cai&s betweentrustee and bene-ciar) but as#between -duciaries*

    •  T%is c#nce(t can be seen in 'ewcases*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    21

  • 8/18/2019 Proprietary Remedies IV

    22/44

    Re Haet 0144" 18 C% 2

    • A s#icit#r %ad de(#sited (art #' %iscient=s ne) int# %is acc#unt w%ic%as# c#&(rised ne) 'r#& %is &arriage

    sette&ent* He &ade vari#us (a)&ent'r#& and int# t%e acc#unt and as#incurred debts* At %is deat% t%e acc#untwas sucient t# &eet cai&s #' t%etrustees in t%e &arriage sette&ent andt%e cient but n#t %is (ers#na debts*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    22

  • 8/18/2019 Proprietary Remedies IV

    23/44

    • Hed + B#t% t%e trustee and t%e cient

    were entited t# c%arge t%e ne) in t%eacc#unt and t%e) %ad (ri#rit) #ver t%egenera credit#rs* Mr* Haet / t%es#icit#r/ st##d in a -duciar) (#siti#n

    t#wards t%e cient*

    •  Gesse MR + Has it ever been suggestedunti recent) t%at t%ere is an) distincti#n

    between an e>(ress trust #r an agent #ra baiee #r a c#ect#r #' rents #ran)b#d) ese in a -duciar) (#siti#n

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    23

  • 8/18/2019 Proprietary Remedies IV

    24/44

    Sincair v Br#ug%a& 01215"AC 824

    •  T%e need t# deter&ine t%e rig%t #' de(#sit#rt# trace int# t%e genera assets #' t%e S#ciet)w%ic% %ad been subject t# winding u(*

    • HOL + T%ere was a -duciar) reati#n betweent%e de(#sit#rs and t%e direct#rs! t%edirect#rs %ad &i>ed t%e 'unds and t%ede(#sit#rs %ad t%e rig%t t# trace t%e& int#

    t%e %ands #' t%e S#ciet) rec#gnising an e?uacai& i' t%e s%are%#ders wit% w%#& t%e)s%ared pari passu

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    24

  • 8/18/2019 Proprietary Remedies IV

    25/44

    Re Di(#c$ 01254" C% 56

    • e>t #' $in were %ed entited t#trace t%e ne) in e?uit) int#c%arities %ands because e>ecut#rscear) st##d in a -duciar)reati#ns%i( t# t%e estate*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    25

  • 8/18/2019 Proprietary Remedies IV

    26/44

    d" Tracing #' Un&i>ed Fund

    • I' t%e trustee %as s#d t%e trust(r#(ert)/ rig%t) #r wr#ng)/ t%ebene-ciar) &a) ta$e t%e (r#ceeds i'%e can identi') t%e&

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    26

  • 8/18/2019 Proprietary Remedies IV

    27/44

    • I' t%e (r#ceeds #' sae %ave been

    used t# (urc%ase #t%er (r#(ert)/t%e bene-ciar) &a)

    • 1" '##w t%e& and &a) eect eit%ert# ta$e t%e (r#(ert) (urc%ased #r%#d it as securit) '#r t%e aunt#' trust aid #ut in t%e (urc%ase

    • 3" %e is entited at eecti#n eit%er

    t# ta$e t%e (r#(ert)• 8" t# %ave a c%arge #n t%e (r#(ert)

    '#r t%e aunt #' trust (r#(ert)*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    27

  • 8/18/2019 Proprietary Remedies IV

    28/44

    •  T%e (#siti#n can be seen in t%e case#' Re Haet=s Estate 0144" 18 C%2

    • It s%a never be vaid against a b#na-de (urc%aser '#r vaue*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    28

  • 8/18/2019 Proprietary Remedies IV

    29/44

    e" Tracing #' Mi>ed Fund

    • A c#&(icated situati#n

    •  T%is is w%en t%e trustee %as &i>ed t%etrust 'unds wit% #t%er ne) #r #t%er

    (r#(ert)*•  T%e (#siti#n #n t%is un&i>ed 'und

    de(ends #n di7erent situati#ns/ eg

    w%et%er t%e #wners%i( #' t%e &i>ed 'und&ust be a((#rti#ned between tw# trust#r a trust and an inn#cent v#unteer*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    29

  • 8/18/2019 Proprietary Remedies IV

    30/44

    i" .%en t%e w%#e bended(r#(ert) is iabe

    •  T%e bene-ciaries wi %ave t%e -rstc%arge #ver t%e &i>ed 'und #r an)(r#(ert) (urc%ased wit% it uness #'

    t%e trustee can (r#ve t%at t%e (art #'t%e &i>ed 'und is %is #wn*

    •  T%e burden is #n t%e wr#ngd#er t#

    s%#w t%at t%e asset #r baancere(resents %is #wn ne)*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    30

  • 8/18/2019 Proprietary Remedies IV

    31/44

  • 8/18/2019 Proprietary Remedies IV

    32/44

    • I' t%e (resu&(ti#n in Re Haet w#r$edunjustice/ it s%#ud n#t be a((ied*

    • Re Oatwa) 128J 3 C% 86* G#)ce G

    • It is/ in &) #(ini#nj/ e?ua) cear t%atw%en an) #' t%e ne) drawn #ut %as beeninvested and t%at invest&ent re&ains in t%ena&e #r under t%e c#ntr# #' t%e trustee K

    %e cann#t &aintain t%at t%e invest&entw%ic% re&ains re(resent %is #wn ne)a#ne**

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    32

    ii" ,#siti#n w%en 'unds #' tw#

  • 8/18/2019 Proprietary Remedies IV

    33/44

    ii" ,#siti#n w%en 'unds #' tw#trusts are &i>ed #r t%at #' trust

    and t%ird (art)

    •  T%is a((ies t# t%e situati#n w%eret%e trustee %as &i>ed t%e 'unds #'tw# trusts/ w%et%er #r n#t wit% %is/ #r%e %as trans'erred t%e 'unds t# aninn#cent v#unteer/ w%# %as &i>ed

    t%e& wit% %is #wn*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    33

  • 8/18/2019 Proprietary Remedies IV

    34/44

    •  T%e rue %ere is t%at t%e tw# trusts #rtrust and t%e v#unteer/ s%are pari

     passe/ i*e* rateab) in t%e &i>ed'unds #r an) (r#(ert) (urc%ased #ut#' ter&

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    34

  • 8/18/2019 Proprietary Remedies IV

    35/44

    Sincair v Br#ug%a& 01215" A*C824

    • Cai& between s%are%#ders andde(#sit#rs in res(ect #' assetsdistributabe b) i?uidat#r in t%e

    winding u( #' a buiding s#ciet)*

    • Hed+ T%e tw# casses s%aredrateab)

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    35

  • 8/18/2019 Proprietary Remedies IV

    36/44

    iii" Mi>ing #' ne) in t%e ban$acc#unt

    • In t%e c#urse w%ere t%ere was a &i>edin a ban$ing acc#unt/ s(ecia rues wi

    a(()

    •  T%ere is %#wever necessar) t#distinguis% t%e (#siti#n between

    trustee and bene-ciaries and asbetween tw# trust and an inn#centv#unteer

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    36

    i" Mi i i b $ t i ti

  • 8/18/2019 Proprietary Remedies IV

    37/44

    i" Mi>ing in a ban$ acc#unt c#nsisting#' t%e trust (r#(ert) and t%e trustee=s

    #wn (r#(ert)

    •  T%e (rinci(es as betweenbene-ciar) and trustee is t%at t%etrustee is (resu&ed t# s(end %isne) -rst*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    37

  • 8/18/2019 Proprietary Remedies IV

    38/44

    Re Haet=s Estate

    • One #' t%e ?uesti#n! %#w t# a#catet%e (a)&ents 'r#& t%e 'und asbetween Haet and t%e cient*

    • Hed+ T%e trustee &ust be (resu&edt# %ave s(ent %is #wn ne) -rstand t# %ave (reserved t%e trust

    ne)*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    38

  • 8/18/2019 Proprietary Remedies IV

    39/44

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    39

    RE HALLETS ESTATE

    •  Gesse MR + it see&s t# &e (er'ect)(ain t%at %e cann#t be %eard t# sa)t%at %e t##$ awa) t%e trust ne)w%en %e %as a rig%t t# ta$e awa) %is#wn ne)* His ne) was t%ere/and %e %ad a rig%t t# draw it #ut and

    w%) s%#ud t%e natura act #' si&()drawing #ut t%e ne) be attributedt# an)t%ing e>ce(t t# %is #wners%i(

    #' ne) w%ic% was at t%e ban$er04/01/16 EQUITY & TRUST IIDR. ZURAIDAH 39

    ii" Mi>ing in a ban$ acc#unt c#nsisting

  • 8/18/2019 Proprietary Remedies IV

    40/44

    ii" Mi>ing in a ban$ acc#unt c#nsisting#' t%e trust (r#(ert) and (r#(ert) #'

    an inn#cent v#unteer

    • A((ied t%e rue in Ca)t#n=s case*

    Ca)t#n=s case (resu&es t%at ne)is (aid #ut #' a current acc#unt in t%esa&e #rder in w%ic% it %ad been(aid*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    40

  • 8/18/2019 Proprietary Remedies IV

    41/44

  • 8/18/2019 Proprietary Remedies IV

    42/44

    '" Increase in vaue

    • A bene-ciar) w#ud be abe t# cai&t%e #rigina ne) ta$en wit% interestand in (ri#rit) t# t%e credit#rs and

    t%at t%e trustee w#ud $ee( a t%e(r#-ts*

    • I' t%e trust increased in vaue/ it

    w#ud be in %is interest t# d# s# and i't%e 'und decrease in vaue/ it w#udbe in %is interest t# %ave a c%arge*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    42

  • 8/18/2019 Proprietary Remedies IV

    43/44

    '" L#ss #' rig%t t# trace

    1" I' (r#(ert) reac%es t%e %ands #' b#na-de (urc%aser '#r vaue wit%#ut

    n#tice

    3" I' t%e cai&ant=s (r#(ert) disa((ears#r t%e (r#(ert) ceases t# be

    identi-abe* eg w%en t%e trust 'und #rt%e (r#ceeds #' t%is sae #' t%e trust%ave been dissi(ated*

    04/01/16 EQUITY & TRUST II(DR. ZURAIDAH)

    43

  • 8/18/2019 Proprietary Remedies IV

    44/44

    8" .%ere tracing w#ud be ine?uitabe

    5" ,a)&ent #' debt* + A trustee w%#used trust (r#(ert) t# disc%arge adebt and n#t%ing w#ud be e't t%atc#ud be said t# re(resent t%e trust(r#(ert)*

    • A debt is a c%##se in acti#n and #nceit %as been (aid it ceases t# e>ist*